- Available:In stock765
- Availability date:2020-07-30
- Dosage form:Capsules
- In stock:765 Items
active ingredients: strains of live lactic acid bacteria Lactobacillus gasseri (L. gasseri), Lactobacillus rhamnosus (L. rhamnosus);
1 vaginal capsule contains at least 108 CFU L. gasseri and not less than 108 CFU L. rhamnosus;
excipients: lactite monohydrate (E 966), corn starch, xanthan gum, anhydrous glucose, magnesium stearate, titanium dioxide (E 171), gelatin.
Dosage form. Vaginal capsules.
Basic physical and chemical properties: white gelatin capsules containing white or almost white powder with a weak characteristic smell and taste.
Pharmacotherapeutic group. Antimicrobial and antiseptic agents used in gynecology. Other antimicrobial and antiseptic agents. Lactobacillus fermentum.
ATX code G01A X14.
Femivag vaginal capsules contain two strains of live lactic acid bacteria that usually dominate the vaginal microflora of healthy women: L. gasseri and L. rhamnosus.
Although the mode of action of vaginal lactic acid bacteria is still being studied, it has been shown to be multifactorial and associated with the action of many factors. Due to the enzymatic production of lactic acid, strains of lactic acid bacteria that dominate the vagina of healthy women maintain low environmental pH values, which inhibits colonization and growth of pathogens. In addition, due to their adhesive properties and the ability to produce hydrogen peroxide and bacteriocins, lactic acid bacteria counteract the invasion of unwanted microorganisms.
- Prevention and treatment of an imbalance of the vaginal bacterial flora, the symptoms of which are itching, dryness, discharge, irritation, unpleasant smell;
- treatment of mild to moderate bacterial vaginosis;
- protection and restoration of the natural balance of the vaginal microflora after treatment with antimicrobial agents.
The use of the drug is contraindicated in case of hypersensitivity to active substances or to any other components of the drug.
Interactions with other drugs and other types of interactions.
There is no information on interactions with other products for vaginal administration.
Special Studies on the interaction of Femivag with other drugs have not been conducted. However, since the lactic acid bacteria that make up the drug are sensitive to the effects of local and systemic antimicrobials, such combination therapy is not recommended.
If symptoms worsen or do not improve after a seven-day course of treatment, patients should consult a doctor. In case of relapse, it is also recommended to consult a doctor.
Use during pregnancy or lactation.
The drug Femivag can be used during pregnancy (for example, for the treatment of bacterial vaginosis of pregnant women).
The drug Femivag can be used during breast-feeding.
Ability to influence the reaction rate when driving vehicles or other mechanisms.
It doesn't affect you.
Dosage and administration.
1 vaginal capsule is inserted deep into the vagina every night before going to bed for 6-8 days.
Immediately after the end of menstruation: 1 vaginal capsule is inserted deep into the vagina every night before going to bed for 4-6 days.
After antibiotic treatment: 1 vaginal capsule is injected deep into the vagina every night before going to bed for 6-8 days.
The drug should not be used for the treatment of children under 12 years of age.
No information available.
There are isolated reports of the development of allergic reactions associated with the use of the drug.